CIK 0001703647
- Non-accelerated filer
- Smaller reporting company
Korro Bio, Inc.
Sign in to watch- Ticker
- KRRO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 472324450
- Phone
- +1 617-468-1999
- Business address
- 60 FIRST STREET, 2ND FLOOR, SUITE 250, CAMBRIDGE, MA, 02141
- Former names
- Frequency Therapeutics, Inc.
- Open-market buys, last 90 days
- $884,752
- in 1 filing
- Open-market sales, last 90 days
- $1,763,410
- in 5 filings, $1.8M under 10b5-1 plans
Net −$878,658. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-07-17 | Lucchino David L. President and CEO | Sale 10b5-1 | −2,775 | $0.68 | $2K | 702,807 |
| 2023-07-17 | Loose Christopher R. Chief Scientific Officer | Sale 10b5-1 | −1,415 | $0.67 | $948 | 196,037 |
| 2023-07-14 | Loose Christopher R. Chief Scientific Officer | Sale 10b5-1 | −906 | $0.59 | $535 | 197,452 |
| 2023-07-14 | Lucchino David L. President and CEO | Sale 10b5-1 | −1,815 | $0.59 | $1K | 705,582 |
| 2023-07-14 | Mitrano Richard J. VP Finance & Operations | Sale 10b5-1 | −148 | $0.60 | $89 | 54,508 |
| 2023-07-13 | Loose Christopher R. Chief Scientific Officer | Sale 10b5-1 | −1,329 | $0.39 | $518 | 198,358 |
| 2023-07-13 | Lucchino David L. President and CEO | Sale 10b5-1 | −2,646 | $0.39 | $1K | 707,397 |
| 2023-07-13 | Mitrano Richard J. VP Finance & Operations | Sale 10b5-1 | −227 | $0.39 | $89 | 54,656 |
| 2023-07-12 | Loose Christopher R. Chief Scientific Officer | Sale 10b5-1 | −1,335 | $0.39 | $521 | 199,687 |
| 2023-07-12 | Lucchino David L. President and CEO | Sale 10b5-1 | −2,649 | $0.39 | $1K | 710,043 |
| 2023-07-12 | Mitrano Richard J. VP Finance & Operations | Sale 10b5-1 | −220 | $0.40 | $88 | 54,883 |
| 2023-07-11 | Loose Christopher R. Chief Scientific Officer | Sale 10b5-1 | −1,363 | $0.37 | $504 | 201,022 |
| 2023-07-11 | Lucchino David L. President and CEO | Sale 10b5-1 | −2,731 | $0.37 | $1K | 712,692 |
| 2023-07-11 | Mitrano Richard J. VP Finance & Operations | Sale 10b5-1 | −228 | $0.37 | $84 | 55,103 |
| 2023-07-10 | Mitrano Richard J. VP Finance & Operations | Sale 10b5-1 | −220 | $0.37 | $81 | 55,331 |
| 2023-07-10 | Lucchino David L. President and CEO | Sale 10b5-1 | −2,591 | $0.38 | $985 | 715,423 |
| 2023-07-10 | Loose Christopher R. Chief Scientific Officer | Sale 10b5-1 | −1,304 | $0.37 | $482 | 202,385 |
| 2023-07-10 | Loose Christopher R. Chief Scientific Officer | Sale 10b5-1 | −1,304 | $0.37 | $482 | 66,023 |
| 2023-07-10 | Loose Christopher R. Chief Scientific Officer | Option exercise 10b5-1 | +4,546 | 70,569 | ||
| 2023-07-10 | Loose Christopher R. Chief Scientific Officer | Option exercise · Restricted Stock Unit 10b5-1 | −4,546 | 131,816 |
Page 13 of 23 · 441 trades